Pharmacokinetics, metabolism and excretion of intravenous [l4C]‐palonosetron in healthy human volunteers
Authors:
- 20 September 2004
- journal article
- clinical trial
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 25 (8) , 329-337
Abstract
Palonosetron (Aloxí(R), Onícít(R)) is a potent, single stereoisomeric 5‐HT3 receptor antagonist developed to prevent chemotherapy‐induced nausea and vomiting. The pharmacokinetics and metabolic disposition of a single intravenous [14C]‐palonosetron (10 µg/kg, 0.8 µCi/kg) bolus dose were evaluated in six healthy volunteers (three males, three females) using serial blood, plasma, urine and fecal samples obtained over 10 days. The safety, tolerability and cardiac effects were assessed. Radiolabeled metabolic characterization revealed that unchanged palonosetron accounted for 71.9% of the total radioactivity in plasma over 96 h, with an extensive distribution volume (8.34 l/kg) and mean plasma elimination half‐life of 37 h. Approximately 83% of the dose was recovered in urine (∼40% as unchanged drug, with 50% metabolized; M9 and M4 were the major metabolites) and 3.4% in feces. Hydrolysis of urine samples suggests that the metabolites are not β‐glucuronide or sulfate conjugates of the parent drug or metabolites. The blood to plasma concentration ratio of the total radioactivity was 1.2, on average, indicating little selective partitioning in erythrocytes. Palonosetron was generally well tolerated; headache was the most frequently reported adverse event. Electrocardiograms and 72 h Holter monitoring revealed no clinically significant changes. Palonosetron circulates in plasma mainly as the parent drug. Renal elimination is the primary excretion route, with parent drug and metabolites M9 and M4 accounting for the majority of palonosetron disposition. These results indicate that both renal and hepatic routes are involved in the elimination of palonosetron from the body. Copyright © 2004 John Wiley & Sons, Ltd.Keywords
This publication has 10 references indexed in Scilit:
- Pharmacokinetic and Safety Evaluation of Palonosetron, a 5‐Hydroxytryptamine‐3 Receptor Antagonist, in U.S. and Japanese Healthy SubjectsThe Journal of Clinical Pharmacology, 2004
- Clinical Science Review: Comparative Review of 5-HT3Receptor Antagonists in the Treatment of Acute Chemotherapy-Induced Nausea and VomitingCancer Investigation, 2000
- 5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and VomitingDrugs, 1998
- Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist.Drug Metabolism and Disposition, 1995
- Pharmacological characterization of RS 25259‐197, a novel and selective 5‐HT3 receptor antagonist, in vivoBritish Journal of Pharmacology, 1995
- The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT3 receptors, in vitroBritish Journal of Pharmacology, 1995
- Pharmacological properties of dolasetron, a potent and selective antagonist at 5‐HT3 receptorsDrug Development Research, 1993
- 5-HT3 Receptor AntagonistsDrugs, 1991
- The concept of selectivity in 5-HT receptor researchEuropean Journal of Pharmacology: Molecular Pharmacology, 1990
- Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population.Journal of Clinical Oncology, 1989